General COVID-19 Information

Emory University is closely monitoring the COVID-19 (novel coronavirus) outbreak. The GA DPH has reported ongoing community transmission of SARS-CoV-2, the virus that causes COVID-19. Emory Healthcare is caring for many patients with COVID-19 both in the hospital and clinics. Emory’s commitment to the health and safety of our community is paramount. A team of representatives from emergency preparedness, health care, campus life, and other units is taking action around-the-clock to protect students, faculty, staff, and visitors. We also continue to work closely with local and state partners to monitor and manage the outbreak. Emory experts are on the front lines of the pandemic — caring for patients, researching possible treatments and vaccines, and sharing knowledge to help inform and prepare the public. Continue to check Emory University’s COVID-19 website for updates on how the pandemic is impacting the university. This is a fluid situation and guidelines and FAQs continue to change.

Emory COVID-19 Website
Hope Clinic on the Front Lines
  • The Hope Clinic is the #1 enrolling site in the NIH Adaptive COVID Treatment Trial with 10% of worldwide study population enrolled here at Emory and Grady by the VTEU and CTU teams.
  • The Hope Clinic is one of first 3 sites that started the first monoclonal antibody study in the US.
  • The Hope Clinic is one of 3 sites conducting the first phase 1 vaccine study in the US (Moderna mRNA vaccine).
  • The Hope Clinic is part of coronavirus prevention network.
  • The Hope Clinic is part of Emory efforts to establish a convalescent plasma collection program.
  • The Hope Clinic is leading an NIH sponsored nationwide effort to better understand the immune responses to COVID-19 in hospitalized patients (IMPACC) and part of other efforts within the CTU and VTEU to better understand the immunology of the virus.

COVID-19 Studies

The Coronavirus Prevention Network is designed to develop the clinical and laboratory pipelines for the rapid implementation of COVID vaccine efficacy trials while conducting groundbreaking scientific investigations.

A clinical trial called CoVPN 5001 will help the newly formed COVID-19 Prevention Network (CoVPN) understand early SARS-CoV-2 infection and the body’s early immune responses to the virus that causes COVID-19 illness. CoVPN 5001 is designed to follow an estimated 800 study participants aged 18 years or older who have tested positive for SARS-CoV-2 infection.

Study participants will be enrolled into one of three groups: those showing no symptoms, those showing mild symptoms, and those showing severe symptoms that require hospitalization. Participants may move between groups if their symptoms worsen over the course of the study. Participation in this study will last for about a month with six visits followed by a health phone call one month after the last visit. Procedures will include one or more blood draw visits and collection of samples such as nasal swab, urine and optional stool samples. Compensation will be provided for time, inconvenience and travel.

A safe and effective vaccine is necessary to reduce morbidity and mortality and aid the global community to return to a thriving social and economic global infrastructure. CoVPN will work to develop and conduct studies to ensure a rapid and thorough evaluation of United States government-sponsored COVID-19 vaccines and antibodies for the prevention of COVID-19 disease.

Eligibility Criteria:

  • 18 years and older
  • Any gender or sexual orientation
  • Positive COVID-19 test within 6 days of enrollment

CoVPN 5001 Press Release: Harmonizing efforts to conduct large scale COVID-19 vaccine efficacy trials

CoVPN 5001 Study Fact Sheet

Please contact Rameses Frederick at or 404-712-9076 if interested in participating. 

Volunteer for CoVPN 5001

This research study is looking at an experimental drug combination REGN10933 and REGN10987 monoclonal antibodies, given as separate subcutaneous (SC, under the skin) injections. The aim of the study is to see how safe, tolerable, and effective the study drugs may be in treating people who have been exposed to SARS CoV-2 by someone in your home and have tested negative virus and are not showing any signs of infection. A monoclonal antibody is a special kind of antibody that is made in a laboratory. Researchers can design these antibodies to fight specific types of infections, such as viruses.

Please contact Nipuni Gomes at or 470-586-4908 if interested in participating.

The purpose of the study is to look at how long and how strongly the immune system responds to COVID-19 infections. Individuals who have been diagnosed with COVID-19 would be eligible to enroll in this study. Participation in this study will consist of coming to the Hope Clinic to have your blood drawn 7 times over a 2-year period. Compensation will be provided for time and travel in the form of $50 for each clinic visit. Participants will not receive any vaccine or treatment during this study. 

Eligibility Criteria:

  • Proof of a confirmed positive test result within the last 60 days
  • Ages 18 years and above
  • HIV-negative

If interested & potentially eligible, please contact Rebecca Fineman at or 404-712-1158. 

Volunteer for the COVID Memory Study

The purpose of the study is to look at how the immune system responds to infections with emerging infectious diseases of public importance. This study will also determine if there are different or better tests that can be used to study these emerging infections.

For more information, please contact Rebecca Fineman at 404-712-1158 or

 Phlebotomy Emergent Study Interest Form

See more information regarding these studies on the COVID-19 page

Volunteer for a COVID-19 Study

Recruiting participants for studies and engaging with the community are what make the research we do possible. Volunteers enable us to carry out our critical mission here at the Hope Clinic. Please fill out this survey if you are interested in participating in any of our studies involving COVID-19 research.

Volunteer for a COVID-19 Study